Literature DB >> 30530071

Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.

Yan Wu1, Lianmei Zhong2, Jia Geng2.   

Abstract

Neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) are inflammatory CNS syndromes mainly involving the optic nerve and/or spinal cord and characterized by the presence of serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). The pathology of NMOSD is complicated, while therapies for NMOSD are limited and only partially effective in most cases. This review article focuses on the main pathology of NMOSD involving AQP4-IgG and lymphocyte function. We also review the existing therapeutic methods and potential new treatments. Experimental NMO animal models are crucial for further research into NMO pathology and treatment. However, no AQP4-IgG-immunized animals have been reported. The establishment of NMO models is therefore difficult and primarily depends on the generation of transgenic mice or transcranial manipulation using human or monoclonal mouse anti-AQP4 antibodies. Advantages and disadvantages of each model are discussed.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APC, antigen-presenting cell; Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; Aqp4, aquaporin 4; Aquaporin-4; BAFF, b-cell activating factor; BBB, blood-brain barrier; BCR, b cell receptor; CDD, complement-dependent cytotoxicity; CFA, complete freund's adjuvant; CSF, cerebrospinal fluid; CXCL, c-x-c motif chemokine ligand; EAE, experimental autoimmune encephalomyelitis; ECD, extracellular domain; Experimental animal models; IGG, immunoglobulin g; IVMP, methylprednisolone pulse; LETM, longitudinally extensive transverse myelitis; MAB, monoclonal antibody; MBP, myelin-binding protein; MOG, myelin oligodendrocyte glycoprotein; MOG-Ab, anti-MOG antibody; NF-H, neurofilament heavy chain; NMO, neuromyelitis optica; NMO-IgG, NMO with serum AQP4-IgG; NMOSD, NMO spectrum disorder; Neuromyelitis optica; Neuromyelitis optica spectrum disorder; PB, plasmablast; PP, plasmapheresis; Remyelination

Mesh:

Substances:

Year:  2018        PMID: 30530071     DOI: 10.1016/j.msard.2018.12.002

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  30 in total

Review 1.  Emerging therapeutic targets for neuromyelitis optica spectrum disorder.

Authors:  Lukmanee Tradtrantip; Nithi Asavapanumas; Alan S Verkman
Journal:  Expert Opin Ther Targets       Date:  2020-03-02       Impact factor: 6.902

2.  Changes in the BTK/NF-κB signaling pathway and related cytokines in different stages of neuromyelitis optica spectrum disorders.

Authors:  Huimin Qiao; Zhuofeng Mao; Wei Wang; Xin Chen; Suhuan Wang; Haolong Fan; Tianyi Zhao; Huiqing Hou; Mei Dong
Journal:  Eur J Med Res       Date:  2022-06-21       Impact factor: 4.981

3.  FTY720 Exacerbates Blood-Brain Barrier Dysfunction Induced by IgG Derived from Patients with NMO and MOG Disease.

Authors:  Shunsuke Yoshimura; Shinsuke Nakagawa; Toshiyuki Takahashi; Keiko Tanaka; Akira Tsujino
Journal:  Neurotox Res       Date:  2021-05-17       Impact factor: 3.911

Review 4.  Targeting the complement system in neuromyelitis optica spectrum disorder.

Authors:  Nithi Asavapanumas; Lukmanee Tradtrantip; Alan S Verkman
Journal:  Expert Opin Biol Ther       Date:  2021-02-16       Impact factor: 5.589

Review 5.  Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives.

Authors:  Giulia Ceglie; Laura Papetti; Massimiliano Valeriani; Pietro Merli
Journal:  Int J Mol Sci       Date:  2020-07-26       Impact factor: 5.923

6.  Late Onset of Neuromyelitis Optica Spectrum Disorders.

Authors:  Yara Dadalti Fragoso; Heloisa Helena Ruocco; Ronaldo Maciel Dias; Hideraldo Cabeça; Ricardo Gonçalves; Nise A de Carvalho Sousa; Caroline Vieira Spessotto; Carlos Bernardo Tauil; Soniza Vieira Alves-Leon; Sidney Gomes; Marcus Vinicius M Gonçalves; Suzana C Nunes Machado; Andrea Anacleto; Eber Castro Correa; Maria Lucia V Pimentel; Gutemberg Augusto C Santos
Journal:  Neurol Ther       Date:  2019-07-02

7.  Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System.

Authors:  Ulises Gómez-Pinedo; Yolanda García-Ávila; Lucía Gallego-Villarejo; Jordi A Matías-Guiu; María Soledad Benito-Martín; Noelia Esteban-García; Inmaculada Sanclemente-Alamán; Vanesa Pytel; Lidia Moreno-Jiménez; Francisco Sancho-Bielsa; Lucía Vidorreta-Ballesteros; Paloma Montero-Escribano; Jorge Matías-Guiu
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

Review 8.  Update on neuromyelitis optica spectrum disorder.

Authors:  Kathryn B Holroyd; Giovanna S Manzano; Michael Levy
Journal:  Curr Opin Ophthalmol       Date:  2020-11       Impact factor: 4.299

9.  Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: A protocol for systematic review and meta-analysis.

Authors:  Mengyu Han; You Chen; Luqi Nong; Ziqiang Liu; Lu Hao; Zhijun Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

10.  Clinical and MRI phenotypes of sarcoidosis-associated myelopathy.

Authors:  Olwen C Murphy; Andrea Salazar-Camelo; Jorge A Jimenez; Paula Barreras; Maria I Reyes; Maria A Garcia; David R Moller; Edward S Chen; Carlos A Pardo
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.